Protagonist Therapeutics Investor Presentation — December 2021

Document content

Dinesh V. Patel, PhD

President & CEODecember 2021COMPANY OVERVIEW

1Forward- looking Statements

2This presentation and the accompanying oral presentation contain forward -looking statements made pursuant to the safe harbor provisions of the Private

Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentatio n, including statements

regarding our future results of operations and financial position, business strategy, product candidates, capital resources, potential markets for our product

candidates, enrollment in our clinical trials, any potential impact on our business related to COVID-19, our potential receipt o f milestone payments and

royalties under our Collaboration Agreement with Janssen Biotech, Inc., are forward -looking statements. In some cases, you can identify forward -looking

statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially” “predict,” “should,”

“will” or the negative of these terms or other similar expressions.

The forward -looking statements made in this presentation involve known and unknown risks, uncertainties and other important fact ors that may cause our

actual results, performance or achievements to be materially different from any future results, performance or achievements expr essed or implied by the

forward-looking statements. These forward -looking statements are subject to risks and uncertainties, including those discussed in Protagonist’s filings with

the Securities and Exchange Commission, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financia l Condition and Results

of Operations” sections of most recently filed periodic reports on Form 10 -K and Form 10-Q and subsequent filings and in the doc uments incorporated by

reference therein. Because forward -looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified

and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future event s. The events and

circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materiall y from those projected in

the forward -looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-lo oking statements

contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. This presentation concerns products that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug